Bristol Myers, J&J halt heart drug trial after interim review
1. BMY and J&J halt late-stage trial for blood clot drug due to review findings. 2. The study is unlikely to achieve its primary objective.
FAQ
Why Bearish?
Halting a late-stage trial can negatively impact BMY's stock. Historical examples show failed drug trials often lead to declining stock prices.
How important is it?
The trial's termination impacts investor confidence and potential future revenues, making it significant for BMY's market perception.
Why Short Term?
Investors typically react quickly to news of drug trial failures, impacting stock price in the short run. Such reactions can be immediate but may stabilize over a few weeks.